A Breakthrough Protein Platform to Treat Inflammatory and Oncological Diseases & Accelerate Drug Discovery
Our Path Forward
Most cellular processes are controlled by interactions between protein molecules, often protein clusters with defined geometry
Traditional therapeutic design is ‘one target molecule – one therapeutic binding interaction’, or two-to-one for antibodies
But most cellular processes involve the simultaneous interaction between several or many protein molecules, or coordinated clusters of receptors that enhance signaling
Therapeutic modalities that can present motifs for binding to multiple target partners present next-generation opportunities
Our proprietary computational methodsare creating novel protein therapeutics that engage their targets through carefully coordinated, avid binding interactions that induce potent agonist responses
We are creating the next generation of biologic agonistsfor the remittive treatment of severe inflammatory and immunediseases
Novel Protein Therapeutic NanoCages
Proprietary technology allows the design of fully human nanoparticles with targeted presentation geometries and sequence composition to deliver potent therapeutics
Architecture, avidity and dosing control agonism
Rapid optimization of NanoCages using AI for I&I
Avid display of targeted payloads with ideal geometry for potent activity
Superior thermal stability, rigidity, and manufacturability of scaffolds
Enables rational drug design for challenging targets
Most cellular proteins are too small to study by cryo EM. <50kD
New strategy developed to use protein cages as large and symmetric scaffolds
Modular design allows for rigid binding of small to medium protein cargos and potentially GPCRs
Structure determination reveals cargo structure and drug complexes
Successful imaging at < 3 Å for SM discovery
We are partnering with pharma and biotech companies to enable structure determination and small molecule therapeutic design
